GALT Galectin Therapeutics
- 1.040
- -0.960-48.00%
- 1.020
- -0.020-1.92%
Galectin Therapeutics News
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients With Cirrhotic Portal Hypertension Caused by MASH
12 Health Care Stocks Moving In Friday's Pre-Market Session
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint
Top Midday Decliners
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
Dow Surges 100 Points, Carnival Earnings Top Views
Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?
Galectin's Belapectin Study Shows Mixed Endpoint Results; Shares Fall Pre-Bell
Galectin Drops as Trial for Lead Asset Fails in MASH
Galectin Therapeutics Shares Are Trading Lower After the Company Announced Top-line Results of Its NAVIGATE Clinical Trial and Confirmed Belapectin Did Not Achieve Statistical Significance.
Express News | Galectin Therapeutics Shares Fall 50% Premarket After Liver Disease Drug Fails to Meet Main Goal in Study
Express News | Galectin Therapeutics Inc - Belapectin Shows Significant Reduction in Esophageal Varices in 2Mg/Kg Cohort
Express News | Galectin Therapeutics Inc - Belapectin Did Not Achieve Statistical Significance in Intent-to-Treat Population
Express News | Galectin Therapeutics Inc - Belapectin Well Tolerated With No Safety Signals
Here's Why Galectin Therapeutics (GALT) Is Poised for a Turnaround After Losing -31.83% in 4 Weeks
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Galectin Therapeutics Presents Clinical Data on NAVIGATE Trial for Esophageal Varices in MASH Cirrhosis at AASLD 2024
Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting
Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
No Data